About us

Who we are ?

About Alesta Therapeutics

Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package. We are excited to announce that our GLP toxicology studies are set to launch in the third quarter of 2024.

Our work is focused on addressing a genetic subtype of Charcot-Marie-Tooth disease, a debilitating peripheral neuropathy. To achieve this, we are combining our in-house expertise with the knowledge of global academic and industry-leading experts. We are proud to collaborate with Professor Dr. Rob Burgess from the Jackson Laboratories, a renowned figure in this field.

OUR team

Investors

Alesta Therapeutics was incorporated by Droia Ventures and is supported by a network of esteemed partners, including Thuja Capital, Praxis Biotech, and Casi Pharmaceuticals. Together, we are committed to advancing innovative treatments that can make a significant difference in the lives of patients.

OUR team